Signal from the log
Sensible Biotechnologies
47 M$ · Series A · United Kingdom
Sensible Biotechnologies fait fabriquer l'ARN messager thérapeutique par des cellules vivantes, qui le modifient naturellement, au lieu de la synthèse chimique habituelle, et l'associe à une conception par IA. Oxford Science Enterprises mène cette série A ; les 47 M$ annoncés comprennent jusqu'à 20 M$ de financement public non dilutif.
Verified
Announced on , logged by the watch of 5 October 2026.
- Operation
- Funding round
- Announced amount
- 47 M$
- Stage
- Series A
- Country
- United Kingdom
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Oxford Science Enterprises , with OTB Ventures , In-Q-Tel , Christoph Huber , Tim Garnett
Provenance
Source businesswire,endpoints
Logged on 5 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.